Mantra Bio is developing targeted therapeutics based on its proprietary exosome engineering platform, REVEAL, which integrates computational biology and bench lab automation. The platform leverages exosome diversity to design therapeutics directed at a wide range of tissue and cellular targets. Its programs include targeted exosome therapeutics for certain ocular diseases and a novel vaccine for infectious disease. The lead program in ophthalmology uses engineered bi‑specific exosomes to precisely target multiple disease pathways. The company is led by CEO Alex Mok and is based in San Francisco, CA. Mantra plans to use recent funding to advance development of its lead targeted exosome therapeutics program and has raised a total of $34M in Series A financing to date. Mantra Bio develops next-generation targeted therapeutics by engineering Targeted Exosome Vehicles (TEVs) using its proprietary REVEAL™ platform. REVEAL integrates computational approaches, wet biology, robotics, a cloud-connected exosome-to-cell-to-tissue database, and machine learning to design, test and optimize TEV candidates in silico and in vitro/in vivo. The company has validated a scalable biomanufacturing process to produce TEVs with high consistency and purity. Mantra intends to build an internal therapeutic pipeline and pursue partnerships to advance TEV-based therapies. Financially, the company announced a $25 million Series A, bringing total investment to date to $30 million following a $5 million seed round. Founded in 2016 and initially developed at Illumina Accelerator, the company is led by CEO and co-founder Alex Mok.

Total raised

$34M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2023